

11th ANNUAL MEETING OF THE LUPUS ACADEMY
Meeting Book

25th March and 8-10th April, 2022



Welcome

Dear Friends and Colleagues,

We are delighted to welcome you to the 11th Annual Meeting of The Lupus Academy[†], which will provide you with new insights into research and clinical practice advances to enrich your knowledge and help you better manage your patients with lupus.

The Lupus Academy is committed to the development of high-quality education and focused on providing new and clinically relevant content through live meeting and online environments, whilst aspiring to support you in your delivery of outstanding patient care and efforts to improve patient outcomes in lupus.

During the past 2 years of the COVID-19 pandemic, Lupus Academy has provided its education through its virtual meeting platform. This year's meeting will be hybrid, with a live meeting in Florence, and parts of the programme broadcast live online and through our catch-up platforms. We look forward to much discussion among faculty and participants both in Florence and online from around the world.

The first part of our meeting will take place online on 25th March 2022, with a 2-hour online session reviewing the place of older lupus treatments and their place in today's treatment of lupus. The main part of the hybrid annual meeting will take place from 8-10th April, with a varied and interesting educational programme, designed to stimulate thinking around current lupus practice and drive discussion both during and outside the meeting sessions.

Delegate feedback from previous annual meetings continues to guide us in selecting the finest topics and speakers for our educational programmes. The scientific component of this year's programme, developed by our Steering Committee of 11 international experts in lupus, provides the opportunity for you to engage with clinicians and scientists, share clinical and scientific experience, and further develop your knowledge in this fast-moving therapeutic area.

We sincerely hope that this meeting will provide you with new ideas for your clinical work, enriched enthusiasm for collaborative research, and fruitful discussions with your colleagues.

We look forward to meeting and talking with you in person and online at the 11th Annual Meeting of the Lupus Academy.

With kind regards,

Professor Eloisa Bonfá

Lupus Academy co-Chair (2022)

Professor Andrea Doria

Lupus Academy co-Chair (2022)

Professor Zahir Amoura

Professor Bernardo Pons-Estel

Professor Richard Furie

Professor Ricard Cervera

Professor Sandra Navarra

Professor Ronald van Vollenhoven

Professor Thomas Dörner

Professor Murray Urowitz

Professor David Isenberg



To participate in polling questions and to post your questions to the faculty, download the interactive voting app [Join at [slido.com #678487](https://slido.com/join/678487)]

Meeting Learning Objectives

The Lupus Academy's 11th Annual Meeting programme will focus on current key issues in lupus clinical practice and is designed to facilitate improved understanding of these issues and their management through both didactic lectures and shared clinical insights in case study workshops. At the end of the programme delegates should be able to:

- Describe the key issues surrounding use of glucocorticosteroids for SLE
- Discuss optimising patient adherence to hydroxychloroquine
- Explain the use of cyclophosphamide in the treatment of lupus nephritis
- Describe the benefits of using LLDAS as an outcome measure and discuss the pros and cons of this in patients with 'true' low disease activity
- Discuss today's role of B cells as a therapeutic target for SLE
- Discuss the role of DOACs in SLE and APS
- Discuss the use of COVID-19 vaccines in patients with SLE and how this affects disease management
- Discuss classification of SLE in line with new molecular markers of disease
- Explain the importance of patient reported outcomes in the evaluation of SLE management
- Demonstrate practical implementation of case-based learning strategies in diagnosis and treatment of cutaneous lupus, lupus nephritis, neuropsychiatric SLE and pregnancy management in SLE and APS
- Discuss the cells (beyond B cells) and cytokines (beyond IFN) involved in the pathogenesis of SLE
- Discuss the place for new and approved therapies for SLE (anifrolumab) and lupus nephritis (belimumab and voclosporin)
- Explain recent developments in measuring disease activity and treatment targets in SLE
- Discuss the value of molecular signatures in kidney biopsies and their relationship to disease activity
- Discuss what drives rapid progression to ESRD in patients with lupus nephritis
- Explain which biomarkers highlight CV risk in women with SLE
- Explain how to manage patients with APS when laboratory scenarios don't fit guidelines
- Discuss the challenges associated with managing cardiovascular disease burden, fatigue, and infection in patients with SLE

Abstracts of the presentations are published in the official journal of the 11th Annual Meeting:

LUPUS
SCIENCE &
MEDICINE™
lupus.bmj.com

Continuing Medical Education



The 11th Annual Meeting of the Lupus Academy has been planned and implemented in accordance with the accreditation requirements of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Siyemi Learning and the Lupus Academy. Siyemi Learning is accredited by the ACCME to provide continuing medical education for physicians.

Siyemi Learning designates this live activity for a maximum of *17 AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Claiming your CME certificate

PLEASE NOTE: You will be able to claim your CME certificate from 22nd April 2022.

Go to LupusCME.org to complete the evaluation and claim your CME Certificate of Attendance.

Sign in with the email address used to register for the meeting; if it is your first time on the site, you will be asked to register.

Disclosures

Speakers' financial disclosures and biographies can be found from Page 14 and on the meeting website. Neither the Lupus Academy planning staff, Julian Ball, Nicole Elzebroek, Eugene Pozniak, nor staff at Siyemi Learning, have any relevant financial relationships with ineligible companies to disclose.



Contents

Programme	8
Biographies	14
Notes	34

Programme

11TH ANNUAL MEETING OF THE LUPUS ACADEMY

Pre-Meeting Session: 25th March 2022

Hybrid Meeting: 8–10th April 2022

Catch-up Content available Online until 30th June 2022
www.lupus-academy.org

Friday 25th March 2022

PRE-MEETING SESSION I: OLD DRUGS ON THE STAGE

(LIVE-STREAMED)

CET (UTC +1 Rome) 14:00 – 16:00 hours

PST (UTC +8 Manila) 21:00 – 23:00 hours

EDT (UTC -4 New York) 9:00 AM – 11:00 AM

Moderators: Eloisa Bonfá (Brazil) & Thomas Dörner (Germany)

14:00	Glucocorticoids for SLE: What are the current questions and issues? Q&A and Discussion (15 Mins)	<i>Guillermo Ruiz-Irastorza (Spain)</i>
14:30	Cyclophosphamide: What is its role in the treatment of lupus nephritis and the new treatment paradigm? Q&A and Discussion (15 Mins)	<i>Liz Lightstone (UK)</i>
15:00	Top 10 tips regarding patient adherence to hydroxychloroquine Q&A and Discussion (15 Mins)	<i>Nathalie Costedoat-Chalumeau (France)</i>
15:30	Panel Discussion (30 Mins)	<i>All</i>
16:00	Close	

Friday 8th April 2022

OPENING SESSION

(LIVE-STREAMED)

CEST (UTC +2 Rome) 13:30–15:45 hours

PST (UTC +8 Manila) 19:30 – 21:30 hours

EDT (UTC -4 New York) 7:30 AM – 9:45 AM

Moderators: Eloisa Bonfá (Brazil) & Ronald van Vollenhoven (Netherlands)		
13:30	Opening Address	<i>Andrea Doria (Italy) & Eloisa Bonfá (Brazil)</i>
	Debate	
13:35	The matter of the debate: LLDAS is an excellent outcome measure, but does it really capture patients with true LDA? (10 Mins)	<i>Ronald van Vollenhoven (The Netherlands)</i>
	YES (20 Mins + 10 Mins Rebuttal)	<i>Eric Morand (Australia)</i>
	NO (20 Mins + 10 Mins Rebuttal)	<i>Andrea Doria (Italy)</i>
	Voting, Q&A and Discussion (20 Mins)	<i>All</i>
Moderators: Andrea Doria (Italy) & Eloisa Bonfá (Brazil)		
	Keynote	
15:05	B cells as a therapeutic target in SLE: Where we are today and where we may be tomorrow Q&A and Discussion (15 Mins)	<i>Thomas Dörner (Germany)</i>
15:45	Break	

PLENARY I: CONTROVERSIAL ISSUES IN THE MANAGEMENT OF SLE

CEST (Paris, Amsterdam, Berlin) UTC +2: 16:15–18:15

Moderators: Andrea Doria (Italy) & Eloisa Bonfá (Brazil)		
16:15	Are DOACs dead? Or do they still have a role in SLE/APS? Q&A and Discussion (15 Mins)	<i>David Isenberg (UK)</i>
16:45	COVID-19 vaccine in lupus patients Q&A and Discussion (15 Mins)	<i>Eloisa Bonfá (Brazil)</i>
17:15	Novel concepts in SLE: Is it time for a new taxonomy? Q&A and Discussion (15 Mins)	<i>Ronald van Vollenhoven (The Netherlands)</i>
17:45	Should PROs be incorporated in the response evaluation? Q&A and Discussion (15 Mins)	<i>Marta Mosca (Italy)</i>
18:15	Close Followed by Evening Networking	

Programme

Saturday 9th April 2022

INTERACTIVE CASE STUDY WORKSHOPS

CEST (Paris, Amsterdam, Berlin) UTC +2: 09:00–10:30

Moderator: David Isenberg (United Kingdom)		
09:00	Management of lupus skin manifestations	<i>Annegret Kuhn (Germany) & Marzia Caproni (Italy)</i>
Moderator: Andrea Doria (Italy)		
09:00	Management of lupus nephritis	<i>Gabriella Moroni (Italy) & Richard Furie (USA)</i>
Moderator: Murray Urowitz (Canada)		
09:00	Management of neuropsychiatric SLE	<i>Dimitrios Boumpas (Greece) & Zahir Amoura (France)</i>
Moderator: Thomas Dörner (Germany)		
09:00	Management of pregnancy in SLE and APS	<i>Angela Tincani (Italy) & Jill Buyon (USA)</i>
10:30	Break	

THIEVES' MARKET

CEST (Paris, Amsterdam, Berlin) UTC +2: 11:00–12:00

Moderators: Zahir Amoura (France) & Eloisa Bonfá (Brazil)		
11:00	Case in practice: Diaries from a long journey Q&A and Discussion (10 Mins)	<i>Edoardo Marrani (Italy)</i>
11:15	Case in practice: I'm becoming "Michelin Man" progressively Q&A and Discussion (10 Mins)	<i>Carolina Aulestia (Ecuador)</i>
11:30	Case in practice: When your mouth pops Q&A and Discussion (10 Mins)	<i>Francisca Guimarães (Portugal)</i>
11:45	Discussion and Awards (15 Mins)	
12:00	Lunch	

PRIME TIME SESSION: TREATMENT TARGETS AND NOVEL THERAPIES

(LIVE-STREAMED)

CEST (UTC +2 Rome): 13:15–15:45 hours

PST (UTC +8 Manila) 19:15 – 21:45 hours

EDT (UTC -4 New York) 7:15 AM – 9:45 AM

Moderators: Zahir Amoura (France) & Murray Urowitz (Canada)		
13:15	Cells involved in SLE: Beyond B cells Q&A and Discussion (15 Mins)	Anne Davidson (USA)
13:45	Cytokines involved in SLE: Beyond IFN Q&A and Discussion (15 Mins)	George Tsokos (USA)
14:15	New and approved therapies for SLE: Anifrolumab Q&A and Discussion (15 Mins)	Ronald van Vollenhoven (The Netherlands)
14:45	New and approved therapies for LN: Belimumab and voclosporin Q&A and Discussion (15 Mins)	Richard Furie (USA)
15:15	Panel Discussion (30 Mins)	
15:45	Break	

INTERACTIVE CASE STUDY WORKSHOPS

CEST (Paris, Amsterdam, Berlin) UTC +2: 16:15–17:45

Moderator: David Isenberg (United Kingdom)		
16:15	Management of lupus skin manifestations	Annegret Kuhn (Germany) & Marzia Caproni (Italy)
Moderator: Andrea Doria (Italy)		
16:15	Management of lupus nephritis	Gabriella Moroni (Italy) & Richard Furie (USA)
Moderator: Andrea Doria (Italy)		
16:15	Management of neuropsychiatric SLE	Dimitrios Boumpas (Greece) & Zahir Amoura (France)
Moderator: Andrea Doria (Italy)		
16:15	Management of pregnancy in SLE and APS	Angela Tincani (Italy) & Jill Buyon (USA)
17:45	Close	

Programme

Sunday 10th April 2022

PLENARY II: CHALLENGES IN LUPUS

CEST (Paris, Amsterdam, Berlin) UTC +2: 08:30–10:30

Moderators: Eloisa Bonfá (Brazil) & David Isenberg (UK)		
08:30	Disease activity and treatment targets in SLE Q&A and Discussion (10 Mins)	<i>Luís Ines (Portugal)</i>
08:55	Molecular signatures in kidney biopsies and their relationship to clinical activity Q&A and Discussion (10 Mins)	<i>Jill Buyon (USA)</i>
09:20	What drives rapid progression to ESRD in patients with lupus nephritis? Q&A and Discussion (10 Mins)	<i>Murray Urowitz (Canada)</i>
09:45	Increased CV risk in women with SLE: Stories from a panel of biomarkers Q&A and Discussion (10 Mins)	<i>Matteo Piga (Italy)</i>
10:10	Panel Discussion (20 Mins)	
10:30	Break	

POSTER SESSION: PRESENTATIONS

CEST (Paris, Amsterdam, Berlin) UTC +2: 11:00–12:00

Moderators: Andrea Doria (Italy) & Eloisa Bonfá (Brazil)		
11:00	Adaptation and validation of the Systemic Lupus Erythematosus Quality of Life Questionnaire (L-QoL) for use in Bulgaria Q&A (5 Mins)	<i>Daliya Tsvetanova Pencheva (Bulgaria)</i>
11:10	Relationship of anti-double stranded DNA antibodies titers and echocardiographic parameters in systemic lupus erythematosus patients Q&A (5 Mins)	<i>Natalia Guajardo-Jauregui (Mexico) & Iris Colunga-Pedraza (Mexico)</i>
11:20	Patients with SLE have unique changes in serum metabolic profiles across age associated with cardiometabolic risk Q&A (5 Mins)	<i>George A Robinson (UK)</i>
11:30	Intercurrent infection as a risk factor for disease flares in patients with systemic lupus erythematosus Q&A (5 Mins)	<i>Fatma el Hadiyen (The Netherlands)</i>
11:40	Transcriptome profiling and autoimmunity-related serological markers identify TP53 and C3aR as drug targets in neuropsychiatric systemic lupus erythematosus Q&A (5 Mins)	<i>Julius Lindblom (Sweden)</i>
11:50	Discussion and Award (10 Mins)	<i>All</i>
12:00	Poster Viewing and Light Lunch	

*More posters available at lupus-academy.org

PLENARY III: DIFFICULT-TO-TREAT LUPUS

(LIVE-STREAMED)

CEST (UTC +2 Rome): 13:00–15:00 hours

PST (UTC +8 Manila) 19:00 – 21:00 hours

EDT (UTC -4 New York) 7:00 AM – 9:00 AM

Moderators: Murray Urowitz (Canada) & Andrea Doria (Italy)		
13:00	APS antibodies: Managing patients when laboratory scenarios don't fit guidelines Q&A and Discussion (15 Mins)	<i>Ricard Cervera (Spain)</i>
13:30	Cardiovascular disease burden in SLE: Risk assessment and management Q&A and Discussion (15 Mins)	<i>Maria Tektonidou (Greece)</i>
14:00	Fatigue in SLE Q&A and Discussion (15 Mins)	<i>Laurent Arnaud (France)</i>
14:30	Infections in SLE Q&A and Discussion (15 Mins)	<i>Sandra Navarra (Philippines)</i>
15:00	Meeting Close	<i>Andrea Doria (Italy) & Eloisa Bonfá (Brazil)</i>

Biographies



Professor Zahir Amoura, MD, MSc

French National Reference Center for SLE and APS, Pitié-Salpêtrière Hospital, Paris, France

Zahir Amoura is Professor of Internal Medicine at the French National Reference Center for Systemic Lupus Erythematosus at Pitié-Salpêtrière Hospital, a role that he has held since 2003.

In 2009, Professor Amoura became Head of the Department of Internal Medicine in the same institution. Professor Amoura completed his Paris Hospital Medical Internship in 1988, and obtained a Master's degree in Immunopharmacology in 1989. He was subsequently awarded his MD (silver medal) in 1993 and his qualifying certification in internal medicine in 1994. Professor Amoura joined the Department of Internal Medicine at Pitié-Salpêtrière Hospital in 1995 as a Senior Lecturer and Senior Practitioner. Professor Amoura has published over 592 peer-reviewed papers, of which 264 focused on the immunopathological features of lupus.

Financial Disclosures

Consultant/Advisor:

AstraZeneca; GSK; Kezar

Grants/Research:

Amgen; AstraZeneca; Bristol Myers Squibb; GSK

All of the relevant financial relationships listed for this individual have been mitigated.



Professor Laurent Arnaud, MD, PhD

Department of Rheumatology, National Reference Center for Autoimmune Diseases (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, France

Following a MD degree at University of Paris and a PhD in immunology at the same institution, Professor Arnaud completed a fellowship program with a specialization in auto-immune diseases, mainly systemic lupus erythematosus (SLE), at Hôpital Pitié-Salpêtrière in Paris. He then pursued post-doctoral clinical research on Systemic Lupus in Stockholm, Sweden and was subsequently appointed full Professor of Medicine at Strasbourg University School of Medicine, Strasbourg, France.

His main research interests focus on the epidemiology of autoimmune diseases with a particular interest in the field of digital health and the use of novel diagnostic and therapeutic strategies based on big data and Artificial Intelligence for the systematic evaluation of biologics and targeted treatments in SLE. With his team at the French National Reference Center for Rare Autoimmune Diseases of Strasbourg (CRMR RESO), he has contributed to more than 180 research projects in the field of rare diseases. Professor Arnaud is an active member of the European Reference Networks for rare diseases ReCONNET & RITA, and has been appointed President-Elect of the European Lupus Society (SLEuro). He is the curator of a twitter account (@Lupusreference) about raising lupus awareness, followed by more than 7,000 people.

Financial Disclosures

Consultant/Advisor:

Alexion; Amgen; AstraZeneca; Abbvie; Biogen; Bristol Myers Squibb; GSK; Janssen; LFB; Lilly; Medac; Novartis; Pfizer; Roche Chugai; UCB

All of the relevant financial relationships listed for this individual have been mitigated.



Financial Disclosures

Eloisa Bonfá does not have any relevant financial relationships with ineligible companies to disclose.

Professor Eloisa Bonfá, MD, PhD

French National Reference Center for SLE and APS, Pitié-Salpêtrière Hospital, Paris, France

Eloisa Bonfá is full Professor of Rheumatology at Hospital das Clinicas HCFMUSP, São Paulo, which is the largest tertiary referral centre for autoimmune rheumatic disorders of Latin America. She is now in her third term elected Clinical Director of Hospital das Clinicas HCFMUSP, University of Sao Paulo.

Professor Bonfá's main clinical and research interest is systemic lupus erythematosus and autoimmunity, with relevant contribution in the field of autoantibodies and original contribution regarding the association of anti-ribosomal P antibodies with psychiatric manifestation of lupus and the first "in vitro" demonstration of the arrhythmogenic potential of purified Ro/ SSA antibodies. She also has described the association of anti-ribosomal P antibodies and lupus membranous nephritis. Hydroxychloroquine for lupus patients is also another field of interest in which she has published on the impact of this drug blood level dynamics in flare rates and the relevance of obesity for drug levels. She has published several papers on vaccine immunogenicity and safety in autoimmune disorders, including H1N1 and yellow fever vaccines. More recently, she has dedicated her efforts to the SARS-Cov-2 vaccine study in a large population of autoimmune rheumatic diseases, with publications in high impact factor journals about not only vaccine response and safety but also long-term antibody decay and booster dose.

Graduating from the University of São Paulo Medical School, Brazil, Professor Bonfá undertook specialist training in Rheumatology in the same University followed by a 4 year rheumatology research fellowship at the Hospital for Special Surgery, New York, USA, under the supervision of Professor Keith Elkon. She has published more than 350 original papers indexed in PubMed and several book chapters.

Professor Bonfá is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the Lupus Academy's 11th Annual Meeting programme and materials.

Biographies



Financial Disclosures

Dimitrios Boumpas does not have any relevant financial relationships with ineligible companies to disclose.

Professor Dimitrios Boumpas, MD, FACP National and Kapodistrian University of Athens, Greece

Dimitrios T. Boumpas graduated from the Medical School at the University of Ioannina in 1983. Following a fellowship in Molecular Immunology at National Institutes of Health (NIH), Bethesda MD, he trained in Internal Medicine at Georgetown University, Washington DC and in Rheumatology-Clinical Immunology at ARB, NIAMS, NIH. Upon the completion of his training, he was appointed an Investigator at ARB, NIAMS, NIH where he served as Deputy and Acting Clinical Director.

In 1999, he returned to the University of Crete to lead the Departments of Rheumatology, Clinical Immunology and Allergy, and Internal Medicine. While in Crete, Professor Boumpas directed the Graduate Program on the Molecular Basis of Human Diseases. In 2012 he joined the Medical School, University of Athens, where he currently serves as the Chairman of the Fourth Department of Medicine at Attikon University Hospital. He is also an affiliate member of the Institute for Biomedical Research of the Academy of Athens.

Professor Boumpas' primary clinical and research interests are in the areas of human autoimmunity with emphasis on systemic lupus erythematosus (SLE) and inflammatory arthritis. His work on the treatment of lupus nephritis has shaped immunosuppressive therapy internationally. He is also a leader in the transcriptomic analysis in human systemic autoimmunity. He has published over 328 peer reviewed scientific papers and 50 book chapters. His research was funded by both National (ΕΠΕΑΕΚ II, Πυθαγόρας I, II, Ηράκλειτος, Θαλής, Αριστεία) and European Union research funds (AUTOCURE FP-6; BTCURE, IMI, HORIZON 2020, ERC Advanced Grants).

Professor Boumpas is Member of the Academia Europaea and President of the Athens Medical Society. He is also past-Chair of the Training and Education Committee for the European League against Rheumatism; Chair of European Task force on SLE that develops guidelines for the management and coordinates clinical trials and research on SLE; Vice Chair ERC Synergy grants; and Associate Editor of Annals of Rheumatic Diseases. He is past-Chair of the European Research Council Panel for Advanced Grants on Diagnostics Tools, Therapies and Public Health (LS-7) and has served on the EU ESRI Committee for Translational Research Infrastructures.



Professor Jill Buyon, MD

**New York University Grossman School of Medicine, Division of Rheumatology,
New York, NY, USA**

Jill Buyon is the Sir Deryck and Lady Va Maughan Professor of Medicine and Director of the Division of Rheumatology at New York University's (NYU) Grossman School of Medicine, New York, USA.

Professor Buyon has devoted more than two decades to understanding and treating systemic lupus erythematosus (SLE) and neonatal lupus (NL), and has significantly advanced the academic literature in these arenas, with >200 peer-reviewed publications to date. In recognition of her contributions, Professor Buyon has earned the distinction of the Lupus Foundation of America's Lifetime Evelyn Hess Achievement Award for Research in SLE, and has served on the National Institute of Arthritis and Musculoskeletal and Skin Diseases advisory council since 2018.

Professor Buyon led the multicentre trial to examine the safety of oestrogens and SLE, and through this effort developed the SELENA-SLEDAI flare index, which has been widely adopted by industry in pivotal trials. She was the NYU site Principal Investigator and collaborator on the largest prospective cohort of pregnant lupus patients, PROMISSE (Predictors of Pregnancy Outcomes: Biomarkers in Antiphospholipid Syndrome and Systemic Lupus Erythematosus). In 1994, Professor Buyon received NIAMS funding to found the Research Registry for Neonatal Lupus (RRNL), a major font of information on this disease (>100 publications).

The highly integrational and bidirectional "bench to bedside" nature of Professor Buyon's research programme utilises basic science to identify markers for risk stratification, predict disease outcomes, and identify potential targets for disease prevention strategies. She established SAMPLE (Specimen and Matched Phenotype Linked Evaluation) at NYU's Division of Rheumatology to facilitate seamless integration of phenotype and sample storage under one biorepository with one protocol and consent. SAMPLE enables sharing of resources and was the platform used to establish the longitudinal METRO cohort for her NIAMS Accelerating Medicines Partnership in which NYU has contributed research tissue from >140 clinically indicated renal biopsies and > 20 biopsies from non-lesional skin.

Financial Disclosures

Consultant/Advisor:

*Bristol Myers Squibb; Equillium;
GSK; Janssen; Ventus*

*All of the relevant financial
relationships listed for this
individual have been mitigated.*

Biographies



Financial Disclosures

Marzia Caproni does not have any relevant financial relationships with ineligible companies to disclose.

Professor Marzia Caproni, MD, PhD

Department of Dermatological Sciences, University of Florence, Italy

Marzia Caproni is the Director of Skin Immunopathology and Rare Dermatological Disease Unit at U.O. Dermatology I, P.O. Piero Palagi, USL Toscana Centro of Florence, University of Florence, Italy and Hospital Manager of Rare Disease for the USL Toscana Centro; Coordinator for Tuscany Region for Rare Dermatological Diseases. Since 15 December 2016, the Centre of Rare Dermatological Disease of USL Toscana Centro has joined the European Rare Network ERN Europeo, recognised among the top 6 in Italy.

Professor Caproni received her medical degree and qualification in Dermatology and Venereology from the University of Pisa, Italy, and qualification in Allergy and Clinical Immunology from the University of Florence. She obtained her PhD in Experimental Dermatology at the University of Naples.

Since 1997 she is an Associate Professor at the School of Specialization in Dermatology, University of Florence.

From 2004 to 2010 and from 2018 to 2021 Professor Caproni was Coordinator of the Italian group for Cutaneous Immunopathology of the Italian Society of Dermatology (SIDEMAST), organising specific national meetings and research projects, some of them with national financing.

Professor Caproni is now a member of three task forces of the European Academy of Dermatology and Venerology (EADV) on cutaneous lupus erythematosus, cutaneous vasculitis and autoimmune bullous diseases. She has contributed to the development of the guidelines for diagnosis, management and monitoring of cutaneous lupus erythematosus and of the addendum for naming and classification of cutaneous vasculitis.

Professor Caproni is author of several publications on lupus and other connective tissue diseases and has a long-standing experience of the clinical management of patients with connective tissue diseases.



Professor Ricard Cervera, MD, PhD, FRCP
Hospital Clinic, Barcelona, Catalonia, Spain

Ricard Cervera is co-Founder and Head of the Department of Autoimmune Diseases at Hospital Clinic, Barcelona. He is also leader of the Research Group on Systemic Autoimmune Diseases at the Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS) and Professor at the University of Barcelona where he coordinates the Master's Course on Autoimmune Diseases and serves as Vice-Dean of Academic Affairs and International Relations at its Faculty of Medicine and Health Sciences. Professor Cervera qualified in medicine in 1983 from the University of Barcelona and received his PhD in 1988 for his thesis on anticardiolipin antibodies. He spent 2 years at the Lupus Research Unit at The Rayne Institute, St Thomas' Hospital, London, UK.

Financial Disclosures

Consultant/Advisor:

AstraZeneca; Bayer; Celgene;
Lilly; GSK; Janssen

*All of the relevant financial
relationships listed for this
individual have been mitigated.*

Professor Cervera is an Associate Editor of the journals *Lupus Science & Medicine* and *European Journal of Internal Medicine* and is on the Editorial Boards of 20 medical journals. He is a Founding Member of the Board of the European Lupus Society and past-coordinator of the European Working Party on Systemic Lupus Erythematosus (Euro-Lupus Group) (1991–2008) and of the European Forum on Antiphospholipid Antibodies (2009–2017). He is Chairman of the Medical Advisory Board of the Catalan Association of Lupus Patients and Medical Advisor to Lupus Europe. He chaired the 6th, 8th and 11th International Congresses on Autoimmunity, the 1st, 2nd and 5th Latin-American Congresses on Autoimmunity, the 5th Meeting of the European Forum on Antiphospholipid Antibodies and the 8th European Lupus Congress.

Professor Cervera's research interests include clinical and epidemiological aspects of systemic autoimmune diseases, particularly SLE and antiphospholipid syndrome, with special focus on its 'catastrophic' variant. He has presented over 300 invited lectures and published more than 800 scientific papers (H-Index, 89), including original articles in the New England Journal of Medicine, The Lancet, Annals of Rheumatic Diseases, Arthritis & Rheumatism, American Journal of Medicine and Medicine (Baltimore). He is co-Editor of 30 books, including 'The Antiphospholipid Syndrome', 'Vascular Manifestations of Systemic Autoimmune Diseases' and 'Diagnostic Criteria in Autoimmune Diseases'.

Biographies



Financial Disclosures

Grants/Research: UCB;
Roche

All of the relevant financial relationships listed for this individual have been mitigated.

Professor Nathalie Costedoat-Chalumeau, MD, PhD

French National Reference Center for SLE and APS, Pitié-Salpêtrière Hospital, Paris, France

Nathalie Costedoat-Chalumeau is Professor of Medicine at Paris University and Senior Hospital Practitioner at the Reference Center for Systemic and Autoimmune Diseases, Department of Medicine, Cochin Hospital in Paris.

Professor Costedoat-Chalumeau research and practice has focused on systemic lupus erythematosus (SLE) and the antiphospholipid syndrome (APS) and she has been involved on studies leading to landmark publications in hydroxychloroquine and its measurement in blood, adherence to treatment, and pregnancy in women with SLE and APS. She designed and successfully led several national and international longitudinal and cohort studies on SLE and APS: the PLUS study, the Adherence study, the GR2 study, and the neonatal lupus cohort. She is currently the principal investigator of the OBILUP study, an open label randomised multicentre controlled trial comparing oral corticosteroids plus mycophenolate mofetil versus obinutuzumab and mycophenolate mofetil as induction therapy for lupus nephritis.

Professor Costedoat-Chalumeau participated as a member of several international EULAR task forces: "Treat to target for SLE"; "Medication of rheumatic diseases in pregnancy"; "Women's health in SLE and APS"; "Remission in SLE"; "Antiphospholipid Syndrome" and was a member of the international EULAR/ACR group that designed the 2019 EULAR/ACR classification criteria for SLE. She is a member of the SLICC group.

Professor Costedoat-Chalumeau has published extensively, including original papers in international journals; she is also a member of the Editorial Boards of the *Lancet Rheumatology* and *Lupus Science & Medicine*.



Financial Disclosures

Anne Davidson does not have any relevant financial relationships with ineligible companies to disclose.

Professor Anne Davidson, MBBS

Zucker School of Medicine at Hofstra/Northwell and Institute for Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, New York, USA

Anne Davidson is Professor of Molecular Medicine at Zucker Hofstra/Northwell School of Medicine and Professor of Molecular Medicine at the Feinstein Institutes for Medical Research, and is a practicing Rheumatologist at North Shore University Hospital. She also serves as Program Director of the Rheumatology Fellowship at Northwell Health.

Professor Davidson received her medical degree from the University of Melbourne in Australia and completed her residency at the Alfred Hospital (Monash University), Melbourne. Her laboratory studies loss of B-cell tolerance in lupus both in mouse models and human systemic lupus erythematosus. The laboratory is also interested in the mechanisms of activation of effector cells within inflamed lupus organs, with a focus on myeloid cells.

Professor Davidson's numerous honors include multiple grants from the National Institutes of Health, the Kirkland Scholar Award, the Dubois Award from the American College of Rheumatology, and the American College of Rheumatology Distinguished Investigator Award.



Professor Andrea Doria, MD University of Padova, Italy

Andrea Doria is Professor of Rheumatology and Head of the Rheumatology Unit and Connective Tissue Disease and Rare Rheumatic Diseases Unit, Department of Medicine, Padova University School of Medicine, Italy. He is also Director of Postgraduate School on Rheumatology of University of Padua.

Professor Doria has long-standing experience of the clinical management of patients with systemic lupus erythematosus (SLE) and other connective tissue diseases. The unit he leads is a tertiary referral rheumatology centre, within Italy, for the diagnosis and management of patients affected with connective tissue diseases and other rare rheumatologic conditions.

He has authored over 450 ISI publications mostly on SLE. These include clinical studies describing new manifestations or subgroups of autoimmune disorders, prognostic risk factors, diagnostic tests and therapeutic interventions, as well as immunochemical studies that evaluate autoantibodies, epitopes and complementary epitopes of autoantigens.

In 2016 Professor Doria founded the European Lupus Society (SLEuro) and was the first President of the Executive Committee. From 2017 until now he has held the role of SLEuro treasurer.

Professor Doria was involved as “expert” in the European League Against Rheumatism (EULAR) Standing Committee for the development of clinical and therapeutic recommendations in SLE. He is a member of the Lupus Academy Steering Committee and co-chaired the 4th Annual Meeting held in Rome 27th February-1st March 2015 and the 9th Annual Meeting held on-line 11-13th September 2020. He was the Chair of the 10th European Lupus Meeting, held in Venice (Italy) 5–8th October 2016 and the Chair of the 14th International Congress on Systemic Lupus Erythematosus virtual meeting held from 6th to 9th October 2021.

Professor Doria is Associate Editor of *Experimental Biology and Medicine* and he participates on the editorial boards of several Rheumatology and Immunology journals: *Lupus*, *Autoimmunity*, *Clinical and Experimental Rheumatology*, *Autoimmunity Reviews*, and *Journal of Autoimmunity*.

Financial Disclosures

Consultant/Advisor:

AstraZeneca; Bristol Myers Squibb; GSK

Speaker: AstraZeneca; Bristol Myers Squibb; Lilly; Galapagos; GSK

All of the relevant financial relationships listed for this individual have been mitigated.

Professor Doria is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the Lupus Academy's 11th Annual Meeting programme and materials.

Biographies



Professor Thomas Dörner, MD
Charité University Hospitals Berlin, Germany

Financial Disclosures

Consultant/Advisor: AbbVie; Bristol Myers Squibb; Lilly; Galapagos; Janssen; Novartis; Roche; UCB

Grants/Research: AbbVie; Bristol Myers Squibb; Lilly; Galapagos; Janssen; Novartis; Roche; UCB

All of the relevant financial relationships listed for this individual have been mitigated.

Thomas Dörner is a board-certified Rheumatologist and Professor of Rheumatology and Hemostaseology at Charité University Hospitals, Berlin, Germany, and group leader at the German Research Center of Rheumatology, Berlin (DRFZ). He qualified in medicine in 1990 at Charité University Hospitals, Berlin, and received his board certification in internal medicine in 1995 before undertaking a postdoctoral fellowship at the University of Texas, Southwestern Medical Center in Dallas, USA, where he researched delineating molecular aspects of B-cell receptor gene usage in autoimmune diseases.

Professor Dörner has received several international and national awards, including the Senior Scholar Award of the American College of Rheumatology, the H Schultze Award of the German League Against Rheumatism, the Randy Fischer Prize for Excellence in flow cytometry and the Schoen Award of the German Society of Rheumatology.

Professor Dörner has served as a member of Editorial Boards of leading journals in rheumatology and immunology, including *Arthritis & Rheumatism*, *Arthritis Research & Therapy*, *Annals of the Rheumatic Diseases*, *Global Arthritis Research Network (GARN)*, *Current Reviews in Rheumatology*, *the Brazilian Journal of Rheumatology*, *the European Journal of Immunology*, *Lupus Science & Medicine*, and *Rheumatology Reviews*.

Professor Dörner has led various clinical trials on rheumatic diseases, including systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, and seronegative spondyloarthropathies. His research interests focus on the characterisation of disturbances of humoral autoimmunity and abnormalities of B cell subsets in the blood versus tissue (lupus, neonatal lupus syndromes, Sjogren's syndrome), exploring innovative therapeutic approaches with particular focus on B-cell directed therapy as well as improving diagnostic tools in autoimmune diseases.



Professor Richard Furie, MD

Zucker School of Medicine at Hofstra/Northwell, New York, USA

Professor Richard Furie, Chief of the Division of Rheumatology at Northwell Health, is a rheumatologist whose activities for several decades have focused on patient care, physician education, and clinical research in the area of anti-rheumatic drug development. He directs The Program in Novel Therapeutics, the Health System's Clinical Research Program in Musculoskeletal Disease. He also directs the Hospital's systemic lupus erythematosus (SLE) and Autoimmune Disease Treatment Center, which has become internationally recognised for its role in the development of new therapies for SLE.

Regarded as one of the senior rheumatologists in the New York metropolitan area, Professor Furie has served as a volunteer for the local chapters of the Arthritis Foundation and the Lupus Alliance, the Lupus Foundation of America, the SLE Foundation, the Lupus Research Alliance, and Lupus Therapeutics. For 20 years he served on many committees of the American College of Rheumatology and was named a Master of the College in 2018. Although often featured as a speaker at national and international conferences, Professor Furie's favourite educational venue is at home with his colleagues and trainees.

Financial Disclosures

Consultant/Advisor:

Aurinia Pharmaceuticals;
Genentech; GSK

Grants/Research: Aurinia
Pharmaceuticals; Genentech;
GSK

*All of the relevant financial
relationships listed for this
individual have been mitigated.*



Professor Luís Inês, MD, PhD

Coimbra University Hospital Centre, Portugal

Luís Inês is Professor of Rheumatology at the School of Health Sciences, University of Beira Interior and Head of the CHUC Lupus Clinic, at the Rheumatology Department, Coimbra University Hospital Centre (CHUC), in Portugal. He earned his doctoral degree in Medicine with research on predictors of clinical outcomes and immunological markers in patients with Systemic lupus erythematosus.

Professor Inês leads the CHUC Lupus Clinic, a tertiary referral center, now following over 400 patients with SLE and integrating multidisciplinary care. He has extensive experience on the clinical management of patients with systemic lupus erythematosus (SLE) and other connective tissue diseases. In addition, he runs a multidisciplinary pregnancy clinic dedicated to the management and follow-up of pregnant patients with inflammatory rheumatic diseases.

Professor Inês is Principal Investigator of the CHUC Lupus Cohort, a long-term prospective cohort study of outcomes and disease measures in SLE patients. Research of his group includes clinical studies on prognostic factors, outcomes, measures of lupus disease activity, disease classification, clinical trials, as well as immunological and biomarker studies. He leads the research group that derived and is developing the SLE Disease Activity Score (SLE-DAS). He has been General secretary of the SLEuro - European Lupus Society since 2019.


Financial Disclosures

Consultant/Advisor:

AstraZeneca; GSK

*All of the relevant financial
relationships listed for this
individual have been mitigated.*

Biographies



Professor David Isenberg, MD, FRCP, FA MS
University College London, UK

Financial Disclosures

Consultant/Advisor:

AstraZeneca; Amgen; Lilly;
Galapagos; Servier

*All of the relevant financial
relationships listed for this
individual have been mitigated.*

David Isenberg is the Versus Arthritis Professor of Rheumatology at University College London (UCL). He graduated from St. Bartholomew's Hospital, London in 1973, and trained in general medicine, rheumatology, neurology, psychiatry and gastroenterology, becoming a Research Fellow at UCL/The Middlesex Hospital in 1979. He was awarded his MD in 1984, based on his studies of myositis. During a year of research at Tufts University, Boston, he became interested in autoantibody structure/function and origin. He was appointed Consultant Rheumatologist in 1984, Professor in 1991 and became the ARC Diamond Jubilee Chair of Rheumatology at UCL in 1996. He has fellowships of both the Royal College of Physicians and the Academy of Medical Sciences.

Professor Isenberg is on the Editorial Boards of five journals, including the Journal of Rheumatology. He is past-Chair of the British Isles Lupus Assessment Group and current Chair of the Lupus UK's Research Committee and was Chair of the Systemic Lupus International Collaborating Clinics group (1998–2003). During the past 20 years, Professor Isenberg has undertaken many roles at the Versus Arthritis charity and was on the Executive Board 2013–2021.

Professor Isenberg is past-President of the British Society for Rheumatology (2004–2006) and he chaired the Society's Biologics Register Committee for 5 years (2006–2011). Professor Isenberg was the 2010 recipient of the Evelyn V. Hess Prize from the Lupus Foundation of America for his contribution to lupus research and treatment. He has authored over 550 original articles, 275 reviews/chapters and 20 books, many on topics related to lupus.

Professor Isenberg's principal clinical interests are the development of disease activity and damage assessment tools in patients with lupus. His specialist interest is in the autoantibodies associated with systemic lupus erythematosus, Sjogren's syndrome, myositis and antiphospholipid antibody syndrome. In 2016 he became a Master of the American College of Rheumatology and in 2017 received the Rheumeritus award from the Portuguese Society for Rheumatology. His alter ego writes and plays for Lupus Dave and The Davettes, probably rheumatology's top rock group.



Professor Annegret Kuhn, MD, MBA

University of Muenster / Hospital Passau, Germany

Annegret Kuhn, MD, MBA, is Professor (adj.) of Dermatology and Venereology at the University of Muenster, Germany, and Visiting Professor at the Amsterdam Medical Center, The Netherlands. Currently, she is Head of the Vaccination Infrastructure Planning Team at the Ministry of Health in Baden-Wuerttemberg, Germany.

Professor Kuhn received her qualification in Dermatology and Venereology at the University of Duesseldorf, Germany, where she also acquired her Doctor of Medicine and her qualification as University Lecturer. She held a Heisenberg-Scholarship from the German Research Foundation (DFG) between 2005 and 2009 and worked in university departments and scientific institutions, such as the Max-Planck-Institute for Molecular Biomedicine, Muenster, and the German Cancer Research Center, Heidelberg, Germany.

Professor Kuhn's major clinical and scientific interest is translational immunology, with particular interest in the pathogenesis, diagnosis, and treatment of skin manifestations in lupus erythematosus. She has also acquired extensive knowledge in all areas of Dermatology and Venereology and has gained long-term experience in academic care of in- and out-patients with autoimmune diseases. Professor Kuhn is Chair of national and international guideline committees and is working on new diagnostic and therapeutic strategies for cutaneous lupus erythematosus. She was Chair of the European Society of Cutaneous Lupus Erythematosus (EUSCLE) between 2004 and 2017 and is member of several German and international medical societies, and reviewer of several clinical and scientific peer reviewed journals. Professor Kuhn has published widely, including more than 150 original and review articles in high impact factor journals.

Financial Disclosures

Consultant/Advisor:

Bayer AG; GSK; Lilly

Grants/Research:

Pharma

Speaker:

Bristol Myers Squibb;

Janssen

All of the relevant financial relationships listed for this individual have been mitigated.



Professor Liz Lightstone, PhD, FRCP

Imperial College London, UK

Liz Lightstone is Professor of Renal Medicine at Imperial College London. She completed medical training at Cambridge University and Kings College Hospital Medical School and her renal training at the Hammersmith Hospital.

Her main research interests are a) in improving outcomes for patients with lupus nephritis (LN), with a particular focus on minimising steroid use, and b) improving outcomes for pregnancy in women with kidney disease. She was the Chief Investigator for the RITUXILUP trial and is national Chief Investigator on two current trials in Lupus nephritis and local Principal Investigator on a further trial.

Professor Lightstone advocates to reduce health inequities in renal medicine, to hear the patient voice in research and support women in nephrology. She is Deputy Chair of the W Europe regional board of the ISN and a member of the ISN ExCom. She is an elected member of the Women in Nephrology Executive Council. She is global co-Chair of the SONG-GD steering committee, until 2022, co-chaired the UK Kidney Research Consortium GN Clinical Study Group, established the Renal RaDar CKD and pregnancy rare disease group, is a member of the OMERACT 2022 SLE Working Group and the International Working Group on Glomerular Diseases and Pregnancy. She has contributed to guidelines on LN and Pregnancy and Kidney Disease, advised NICE in these areas and is on the Advisory Board of Nature Rev Nephrology. She is a Trustee of Kidney Research UK and serves on their Research Strategy and Nominations and Governance Committees.

In the past 2 years she has developed expertise in the management of severe COVID pneumonitis, co-chairs her NHS Trust's COVID Treatment and Guideline Group, and has published extensively on the immune response to COVID and outcomes of COVID in kidney patients with a particular focus on those with immune mediated kidney disease.

Financial Disclosures

Consultant/Advisor:

Alexion; AstraZeneca; Biogen;

Bristol Myers Squibb; GSK;

Kezar; Novartis; Pfizer

Speaker:

Alexion; GSK;

Novartis

All of the relevant financial relationships listed for this individual have been mitigated.

Biographies



Professor Eric Morand, MBBS (Hons), FRACP, PhD
Monash University, Melbourne, Australia

Eric Morand is Professor of Medicine and Head of the School of Clinical Sciences at Monash University, and Head of Rheumatology at Monash Health, in Melbourne, Australia.

Eric graduated from Medicine at Monash University, trained in clinical rheumatology in Australia and at the Royal National Hospital for Rheumatic Diseases, UK and took his PhD at Monash University. His laboratory research focusses on glucocorticoid-induced proteins in the immune system, and his clinical research on systemic lupus erythematosus (SLE). He founded the Lupus Clinic at Monash Health, and the Asia Pacific Lupus Collaboration (APLC), now among the largest longitudinal cohorts of SLE patients ever assembled. The APCL has focused on developing and validating new endpoints for SLE clinical research, including developing and validating the Lupus Low Disease Activity State (LLDAS) endpoint, now widely incorporated in clinical trials. He also led the TULIP2 trial of anifrolumab in SLE, resulting in regulatory approval of anifrolumab in the US, Japan, and EU. In 2017 he chaired the International Congress on SLE.

Professor Morand's awards include the William E Paul Distinguished Innovator Award of the Lupus Research Alliance, New York, and the Parr Prize of the Australian Rheumatology Association. In 2021 he was inducted into the Honour Roll of Monash University.

Financial Disclosures

Consultant/Advisor:

AstraZeneca; Amgen; Biogen;
Bristol Myers Squibb; Capella;
Lilly; EMD Serono; Genentech;
GSK; Janssen; Servier; Wolf;
Zenas

Grants/Research:

AstraZeneca; Bristol Myers
Squibb; Lilly; EMD Serono;
GSK; Janssen

*All of the relevant financial
relationships listed for this
individual have been mitigated.*



Professor Gabriella Moroni, MD
Department of Biomedical Sciences, Humanitas University, IRCCS Humanitas
Research Hospital, Milan, Italy

Gabriella Moroni is Professor of Nephrology at the Department of Medical Science at Humanitas University and Senior Consultant at Nephrological Unit of IRCCS Humanitas Research Hospital, Milan, Italy. Professor Moroni Graduated (magna cum laude) from Medical school at University of Pavia in 1981 and received a Master's Degree (magna cum laude) in Occupational Medicine in 1985 at the same University before completing a Master's Degree (magna cum laude) in Nephrology at the University of Modena in 1989.

Professor Moroni has longstanding experience in the histological and clinical management of lupus nephritis, renal systemic vasculitis and other connective tissue diseases. Her other main scientific interests include primitive and secondary glomerulonephritis in particular evaluation of their renal histology, treatment and prognosis, recurrence, and *de novo* glomerular diseases in kidney transplant, idiopathic and IgG4 forms of retroperitoneal fibrosis.

Professor Moroni has been invited speaker in numerous international meetings, she is author or co-author of more than one hundred papers and book chapters. She is member of the Editorial board of *Lupus*, *Journal of Nephrology* and reviews papers for a number of International Journals. She has been involved in a number of clinical trials, including some on lupus nephritis.

Financial Disclosures

Speaker:

Aurinia
Pharmaceuticals; GSK; Otsuka

*All of the relevant financial
relationships listed for this
individual have been mitigated.*



Professor Marta Mosca, MD
University of Pisa, Italy

Marta Mosca is Professor of Rheumatology at the University of Pisa and Head of the Rheumatology Unit at the Azienda Ospedaliera Universitaria Pisana, Italy. She is also the Director of Fellowship Training Program in Rheumatology at the University of Pisa. Since December 2016 she has been the Coordinator of the European Reference Network on “Rare and Hereditary Connective and Musculoskeletal Diseases” (RECONNET) promoted by the European Commission.

Professor Mosca is also the coordinator of the European Commission Program INTEGRATE, which aims at integrating the physician and the patients’ point of view in systemic lupus erythematosus (SLE). She is also a member of the Scientific Advisory Board of LUPUS EUROPE. Since November 2019, she has been member of the Systemic Lupus Erythematosus International Collaborating Clinics Group.

Professor Mosca has participated in the development of EULAR recommendations for the management of SLE, for women’s health, for the management of antiphospholipid syndrome in adults, and has coordinated the Development of recommendations for monitoring SLE patients in clinical practice and in observational studies. She was a member of the EULAR-ACR Steering Committee for the development of Classification Criteria for SLE.

Financial Disclosures

Consultant/Advisor:

AstraZeneca; GSK; Lilly

Speaker: AstraZeneca; GSK; Lilly

All of the relevant financial relationships listed for this individual have been mitigated.



Professor Sandra Navarra, MD
University of Santo Tomas, Manila, Philippines

Sandra Navarra is Professor and Head of Rheumatology at University of Santo Tomas Hospital, Manila, Philippines. She served as Secretary-General, head of the Education Committee, co-chaired the special interest group on systemic lupus erythematosus (SLE) of the Asia Pacific League of Associations for Rheumatology (APLAR), and is past-President of the Philippine Rheumatology Association.

Professor Navarra is Director of the Lupus Inspired Advocacy (LUISA) Project for lupus education and research, and the People Empowerment for Arthritis and Lupus (PEARL) Movement for lay education and medical assistance programmes, both administered by Rheumatology Educational Trust Foundation Inc. (RETFI). Professor Navarra is a member of the Lupus Academy Steering Committee, and a founding and executive board member of both Asia Pacific Lupus Collaboration (APLC) and Asian Lupus Nephritis Network (ALNN).

Professor Navarra has published widely in the field of lupus and other rheumatic diseases and is the recipient of several university, national and regional awards for her contributions to education and research, including the Philippine College of Physicians Most Distinguished Physician award and the APLAR Master award. She has organised several national and regional educational meetings including the Ten Topics in Rheumatology – Asia (November 2009), first Asian Lupus Summit (November 2012), Asian Lupus Summit by Lupus Academy (March 2014), Lupus Academy (Philippine) Roadshow Meetings (May 2016, November 2017, May 2018), Lupus for the Internist (May 2019) and Lupus webinar series (October-December 2020).

Financial Disclosures

Consultant/Advisor: Biogen; Boehringer

Grants/Research: Astellas, Aurinia Pharmaceuticals; Lilly; Novartis

Speaker: Boehringer Ingelheim, GSK; Janssen; Novartis; Pfizer

All of the relevant financial relationships listed for this individual have been mitigated.

Biographies



Professor Matteo Piga, MD
University of Cagliari, Italy

Professor Matteo Piga is an Associate Professor of Rheumatology at the University of Cagliari (Italy).

Professor Piga received his medical degree (2003) and qualification in rheumatology (2007) from the University of Cagliari. Between 2007 and 2008, he was an Honorary Research Fellow at the Louise Coote Lupus Unit at St. Thomas's Hospital, London, UK. In 2010 he had re-joined the University of Cagliari as a researcher (2010-2019) and then as Associate Professor (2019-present). He is a member of the European Lupus Society (SLEuro).

Professor Piga's main scientific interest is systemic lupus erythematosus. His current research topics include immunogenetics, epidemiology, developing biomarkers and other tools for assessing disease activity and organ damage, implementing telemedicine and musculoskeletal ultrasound to diagnose and monitor the disease. In addition, he is enthusiastically involved in rheumatology training programmes primarily focused on the management of connective tissue diseases.

Professor Piga has contributed to more than 110 publications (PubMed) in the field of rheumatic diseases.

Financial Disclosures

Consultant/Advisor:
AstraZeneca; GSK

All of the relevant financial relationships listed for this individual have been mitigated.



Professor Bernardo Pons-Estel, MD
Regional Center for Autoimmune and Rheumatic Diseases and the Cardiovascular Institute of Rosario, Argentina

Bernardo Pons-Estel is Head of the Regional Center for Autoimmune and Rheumatic Diseases (CREAR), and the Cardiovascular Institute of Rosario (ICR), Argentina. He received his medical degree from the National University of Rosario and went on to train in rheumatology, first in Argentina (Rosario) and thereafter the USA, where he was a fellow at New York University (Bellevue Hospital and the Irvington House Institute, New York) and at the University of Missouri Cancer Research Center, Columbia.


Professor Pons-Estel is the main coordinator for the Latin American Group for the Study of Systemic Lupus Erythematosus (GLADEL), the Genomic Study of Latin-American Patients with SLE (GLA-GENLES) and the Latin American Group for the Study of Rheumatic Diseases in Indigenous People (GLADERPO). He is past-President of the Argentinean Rheumatology Society (2011–2013). In 2013, he chaired the 10th International Congress on SLE, which took place under GLADEL sponsorship in Buenos Aires, Argentina and in 2018 he chaired the Pan-American League of Rheumatology Associations (PANLAR) Congress in Buenos Aires.

Professor Pons-Estel is a council member of the Science and Educational Committee of the Pan-American League of Association for Rheumatology (PANLAR). He is also an active member of the Systemic Lupus International Collaborating Clinics (SLICC), member of the Lupus Academy Steering Committee and an International Member of the ACR. Recently, a collaboration between GLADEL and PANLAR materialised, the aim being the development of guidelines for the management of SLE patients from the Latin American subcontinent; Bernardo is an integral part of this collaboration.

Financial Disclosures

Grants/Research: GSK;
Janssen

All of the relevant financial relationships listed for this individual have been mitigated.



Financial Disclosures

Guillermo Ruiz-Irastorza does not have any relevant financial relationships with ineligible companies to disclose.

Professor Guillermo Ruiz-Irastorza, MD, PhD **Autoimmune Research Unit at Cruces University Hospital, Bizkaia, Spain**

Guillermo Ruiz-Irastorza received his MD from the Universidad Autónoma de Madrid, Spain in 1990 and became a specialist in Internal Medicine in 1996. Following his PhD from the University of the Basque Country, Spain in 1999, he spent a year as a Research Fellow at the Lupus Research Unit, St Thomas' Hospital, UK, before returning to the Hospital Universitario Cruces as Consultant Physician in Internal Medicine. Since 2010 he has lead the Autoimmune Diseases Unit at Cruces University Hospital, Bizkaia, Spain.

Professor Ruiz-Irastorza became Professor of Medicine at the University of the Basque Country, Spain in 2004. He is the coordinator of the Autoimmune, Inflammatory and Infectious Diseases area of Biocruces Bizkaia Health Research Institute, and also leads the Autoimmune Diseases Research group.

Professor Ruiz-Irastorza's clinical and research interests focus on systemic lupus erythematosus, antiphospholipid syndrome, and pregnancy and autoimmune diseases. He is author of 217 peer-reviewed publications. His group has contributed to better define the role of antimalarials and different doses of glucocorticoids in the treatment of lupus.

He is a member of the Editorial Board of Lupus, and a reviewer of several journals in the fields of Rheumatology and Autoimmune diseases, including *Annals of Rheumatic Diseases*, *Arthritis & Rheumatology*, *Rheumatology*, *Journal of Rheumatology*, *Lupus Science & Medicine*.

He enjoys reading comic-books and graphic novels, being Daredevil, the blind super-hero, his favourite character.



Professor Maria Tektonidou, MD

University of Athens, Greece

Financial Disclosures

Maria Tektonidou does not have any relevant financial relationships with ineligible companies to disclose.

Maria Tektonidou is Professor of Rheumatology, Head of Rheumatology Unit, and Head of the National Center of Expertise for Rare and Complex Connective Tissue and Musculoskeletal Diseases at the First Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens, Greece. She is also a member of the Executive Board of the Joint Academic Rheumatology program, School of Medicine, National and Kapodistrian University of Athens, EULAR Centre of Excellence (2021-2026). She completed her residency in Rheumatology in 2000 and her PhD in 2001 (University of Athens). She worked on health outcomes as a Guest Researcher (1-2 monthly visits/year) at the NIAMS/NIH (2009-2019).

Professor Tektonidou is a member of the Executive Committee of the “European Lupus Society-SLEuro” (2018-present) and a member of the Steering Committee. Between 2014 and 2021, she was Executive Committee member of the ‘AntiPhospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION)’. Since 2019, she has led the EULAR Antiphospholipid syndrome study group.

Professor Tektonidou has participated as an expert in the ‘EULAR recommendations for the management of systemic lupus erythematosus (SLE) with neuropsychiatric manifestations’, the ‘Joint EULAR/ERA-EDTA recommendations for the management of adult and paediatric lupus nephritis’, the ‘EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with SLE and/or APS’ and the “2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus”. She is a member of the Steering Committee of the “ACR/EULAR Classification Criteria for Antiphospholipid Syndrome” ongoing project.

She has recently convened the “EULAR Recommendations for the management of APS in adults” (2019), and the “EULAR recommendations for the cardiovascular management of rheumatic diseases including SLE and APS” (2022). She is currently convening the “Development and Validation of a EULAR disease activity score in Antiphospholipid Syndrome” project. She is leading the “SURvey of cardiovascular Risk Factors (SURF) in SLE and APS” project including 29 participating centres from four continents.

Professor Tektonidou’s major research interests include epidemiology, outcomes research, comorbidities, health-related quality of life, and management of patients with systemic autoimmune diseases, especially APS and SLE. She was invited speaker at several national and international meetings. She has over 200 peer-reviewed publications in international journals and book chapters with 12,700 citations and h-index 47 (Google Scholar). She is on the editorial board of four international journals (including one Associate Editor position) and served as a reviewer for 60 international journals.



Professor Angela Tincani, MD

University of Brescia, Italy

Professor Angela Tincani is senior consultant at Rheumatology and Clinical Immunology Unit in the at the “ASST-Spedali Civili di Brescia”, Italy and professor at Rheumatology Specialization, University of Brescia, Italy. She was previously Head of the Rheumatology and Clinical Immunology Unit at the “ASST-Spedali Civili di Brescia”, Italy.

Professor Tincani has been Committee Member or Chair of many international conferences on systemic lupus erythematosus, antiphospholipid antibodies, autoimmunity, and pregnancy in rheumatic diseases. She was involved in the EULAR task forces as an “expert” for the development of recommendations.

She has authored more than 300 publications on the management of patients with systemic autoimmune diseases. Several articles focus on reproductive related issues such as: 1) management of patients with rheumatic diseases during pregnancy; 2) use of anti-rheumatic drugs during pregnancy and lactation; 3) evaluation of different autoimmune diseases and autoantibodies as risk factors for poor gestational outcomes.

Professor Tincani has a recognised experience in the clinical management of patients with autoimmune rheumatic diseases. In addition, is responsible of the multidisciplinary Pregnancy Clinic in Rheumatic Diseases since 1990.

Financial Disclosures

Consultant/Advisor:

Novartis; UCB

Speaker: GSK; Janssen; UCB

All of the relevant financial relationships listed for this individual have been mitigated.



Professor George Tsokos, MD

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

George Tsokos is a Professor of medicine at Harvard Medical School and Chief of the Division of Rheumatology and Clinical Immunology at Beth Israel Deaconess Medical Center in Boston, Massachusetts, USA.

Professor Tsokos' laboratory has led the field of molecular abnormalities on immune cells in patients with systemic lupus erythematosus and has identified previously unknown pathways that have served as the basis for novel treatments currently in various phases of development. More recently, he has launched studies to decipher the interaction between immune and kidney resident cells and to identify local processes that enable renal injury.

Professor Tsokos' has served in various leadership positions, including president of the Clinical Immunology Society, the member of the boards of directors for the American College of Rheumatology (ACR) and the Lupus Foundation of America, member or Chair of multiple federal study sections, and Editor or member of the editorial boards for top scientific journals. He holds a MERIT Award from the National Institutes of Health and has received the Kirkland, the Lee C. Howley Sr. and Evelyn Hess awards; the Distinguished Basic Investigator Award from the ACR; the Lupus Insight Prize from the Lupus Research Alliance; the Carol Nachman Prize for Rheumatology. He is a Master of the American College of Physicians and the ACR, a member of Association of American Physicians and Fellow of American Association for the Advancement of Science.


Financial Disclosures

Consultant/Advisor: A2

Therapeutics; Cugene

Grants/Research: Janssen

All of the relevant financial relationships listed for this individual have been mitigated.



Professor Murray Urowitz, MD

University of Toronto, Canada

Professor Murray Urowitz is a Senior Staff Rheumatologist at the Toronto Western Hospital and Senior Scientist at the Krembil Research Institute and Schroeder Arthritis Institute, Canada. He is also currently Professor of Medicine at the University of Toronto and Director of the Centre for Prognosis Studies in the Rheumatic Diseases and the Lupus Clinic at the Toronto Western Hospital.

Professor Urowitz was a founding member of the Systemic Lupus International Collaborating Clinics (SLICC) group and currently directs the SLICC Registry for Atherosclerosis. In 1995 he was the recipient of the Distinguished Rheumatologist Award of the Canadian Rheumatology Association and in 2009 he was recipient of the Evelyn V. HESS Award for outstanding contributions to lupus research, awarded by the Lupus Foundation of America. He was the recipient of the Queen Elizabeth Diamond Jubilee Medal for longstanding contributions to lupus research work in the field of rheumatology in 2015. In 2017 he was awarded the Distinguished Clinical Investigator Award for exceptional contributions to the field of rheumatology by the American College of Rheumatology. In May 2019 was the recipient of the University of Toronto Dean's Alumni Lifetime Achievement Award for Global Impact.

Professor Urowitz has published 447 peer-reviewed papers and 46 book chapters. He has supervised the training of over 140 fellows in rheumatology especially in systemic lupus erythematosus.

Financial Disclosures

Consultant/Advisor:

AstraZeneca; GSK; Lilly;
Syneos; UCB

Data Safety Monitoring

Committees: UCB

Grants/Research: GSK

All of the relevant financial relationships listed for this individual have been mitigated.



Professor Ronald van Vollenhoven, MD, PhD

Amsterdam University Medical Centers, and Amsterdam Rheumatology & Immunology Center, The Netherlands

Professor Ronald van Vollenhoven is Chair of the Department of Rheumatology and Clinical Immunology at the Amsterdam UMC and Director of the Amsterdam Rheumatology Center (ARC) in Amsterdam, the Netherlands.

He received his MD and PhD degrees from the University of Leiden in The Netherlands. After graduating in 1984 he pursued immunology research at Cornell Medical College in New York, followed by residency (specialty training) in Internal Medicine at the State University of New York at Stony Brook, and at Stanford University, USA, leading to an American Board of Internal Medicine certification in both Internal Medicine and Rheumatology.

From 1993 to 1998 Professor van Vollenhoven held a faculty appointment as Assistant Professor of Medicine in the Division of Immunology and Rheumatology at Stanford University, and from 1995 he was the Medical Services Chief and Fellowship Director in that division. In 1998 he moved to Stockholm, Sweden, where he worked as a Senior Physician and Chief of the Clinical Trials Unit in the Department of Rheumatology at the Karolinska University Hospital and Associate Professor of Rheumatology; in 2010, he was appointed as Professor and Chief of the Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID) at the Karolinska Institute.

In January 2016 Professor Vollenhoven was appointed as Professor of Rheumatology at the University of Amsterdam and the VU University, and Chair of Rheumatology at both the AMC and VUMC hospitals, which in 2018 merged into the Department of Rheumatology and Clinical Immunology of the new Amsterdam UMC. He is also the Director of the ARC.

Professor van Vollenhoven's research interests focus around the development and systematic evaluation of biological and immunomodulatory treatments for the rheumatic diseases. With his co-workers, he established the Stockholm registry for biological therapies (the STURE database), which supported research projects relating to clinical efficacy, pharmacology, outcomes and pharmacoeconomics. He has been Principal Investigator in many clinical trials of novel therapies in rheumatic diseases and has contributed to a number of important investigator-initiated trials including the SWEFOT, ADMIRE, and DOSERA trials. He has published over 400 original papers (H-index: 75), book chapters and reviews, and is associate-editor of Dubois' *Lupus Erythematosus* (Elsevier, 2014), editor of the textbook *Clinical Therapy Research in the Inflammatory Diseases* (World Scientific Press, 2015), author of the monograph *Biological Therapy of Rheumatoid Arthritis* (Springer, 2015) and co-author, with Professor Laurent Arnaud, of the *Handbook of Systemic Lupus Erythematosus* (Springer, 2017). In 2004, Professor van Vollenhoven was awarded the Scandinavian Research Foundation Prize for excellence in clinical research in rheumatology, and he is an honorary member of several rheumatological societies, and in 2019 he was awarded the Dutch Rheumatology Society's highest award, the Jan van Breemen medal. He is the Editor-in-Chief of *Lupus Science & Medicine*, Vice-Chair of the EULAR Research Committee, Member of the EULAR, co-founder of the IRBIS registry for biologics in SLE, the CERERRA registries collaboration and the NORD-STAR collaboration for Nordic trials in the rheumatic diseases, and the initiator of the Treat-to-Target-in-SLE and DORIS initiatives.

Professor van Vollenhoven is married and has two grown-up children and in his spare time he plays classical piano.

Financial Disclosures

Consultant/Advisor:

AbbVie; AstraZeneca; Biogen; Biotest; Bristol Myers Squibb; Galapagos; Gilead; Janssen; Pfizer; Sanofi; Servier; UCB; Vielabio

Grants/Research:

Bristol Myers Squibb; GSK; Lilly; Pfizer; Roche; UCB

Speaker:

AbbVie; Galapagos; GSK; Janssen; Pfizer; UCB

All of the relevant financial relationships listed for this individual have been mitigated.

About the Lupus Academy

Mission

The Lupus Academy is a not-for-profit, long-term initiative committed to improving patient outcomes in SLE and allied diseases. By providing a highly interactive educational forum, the Lupus Academy is dedicated to sharing best clinical practice through the dissemination and discussion of cutting edge scientific and clinical research.

Meeting Organisation

The 11th Annual Meeting of the Lupus Academy has been developed under the control of the meeting Chairs: Professor Eloisa Bonfa (Brazil) and Professor Andrea Doria (Italy), on behalf of the Steering Committee of the Lupus Academy, and with the support of the planning staff at Lupus Academy. It has been developed in Joint Providership with Siyemi Learning, an ACCME-accredited provider for CME compliance and certification. No other individuals or organisations have had any influence over the content of this meeting.

Other Educational Activities

The Lupus Academy runs an Annual Meeting and several regional Roadshow Meetings each year. It also has an extensive library of presentations that is available to registered members, currently free of charge. The Lupus Academy presents its accredited online education at LupusCME.org. From 2019 Lupus Academy has been proud to be the provider of the eLearning course on SLE for the European League Against Rheumatism (EULAR).

More information about all Lupus Academy educational activities can be found at lupus-academy.org.

Further Information

The Lupus Academy is a not-for-profit educational foundation with its office in the Netherlands, KvK 54535891

Lupus Academy Foundation
Maasdijk 409
4264 AS Veen
The Netherlands

Supporters



LupusAcademy
Communicate. Educate. Treat.

Financial Supporters

Independent Educational Grant
GSK

Platinum Sponsor
BMS

Gold Sponsor
Janssen

Silver Sponsor
Aurinia

Bronze Sponsor
AbbVie, Biogen, Galapagos, UCB



11th Annual Meeting **8-10 April 2022** **Florence**

In-kind Supporters



Financial and in-kind support is only accepted on a strictly “hands-off” basis, where the supporting companies do not have any control or influence over the planning, content, speaker selection or execution of educational activities. Support is received as educational grants, sponsorship, donations or in-kind, and where used, clearly identified.

[illegible]



This image shows a full page of white paper with horizontal blue lines, resembling notebook paper. The lines are evenly spaced and run across the width of the page. There is no handwriting or other markings on the paper.



Communicate. Educate. Treat.

[illegible]

This image shows a full page of blank, lined paper. It features approximately 20 evenly spaced horizontal blue lines across its entire width. The paper is otherwise completely empty, with no margins, text, or other markings.



Communicate. Educate. Treat.

[illegible]

[illegible]



This image shows a single sheet of white paper with horizontal blue ruling lines. The lines are evenly spaced and run across the width of the page. There is no text or other markings on the paper.



This image shows a full page of white paper with horizontal blue lines, resembling notebook paper. The lines are evenly spaced and run across the width of the page. There is no handwriting or other markings on the paper.



[illegible]



